The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Congressionally Directed Medical Research Programs (CDMRP) -- Tuberous Sclerosis Complex Research Program -- Clinical Translational Research Award
The Clinical Translational Research Award supports studies that will move promising, wellfounded preclinical and/or clinical research findings closer to clinical application, including diagnosis, prognosis, or treatment of TSC. Projects supported by this award mechanism may include, but not limited to:
- Studies moving from preclinical to clinical research and/or the reverse, analyzing human anatomical substances and/or data associated with completed clinical trials (such as correlative studies that investigate the correlation of a set of genetic and/or environmental factors with disease progression, or the effect of an intervention on the disease outcomes, etc.)
- Studies advancing clinical trial readiness through development of biomarkers, clinical endpoints, and validation of pharmacokinetics/pharmacodynamics.
- Pilot clinical trials where limited clinical testing (e.g., small sample size) of a novel intervention is necessary to inform the next step in the continuum of translational research.
Preclinical studies may be appropriate but must include a clinical component. Projects that are strictly animal research will not be considered for funding and should consider other FY22 TSCRP funding opportunities.
• Required Pre-Application Deadline: June 30, 2022
• Application Submission Deadline: July 28, 2022
Areas of Interest
The FY22 TSCRP Clinical Translational Research Award encourages applications in biomarkers, therapeutics, and patient-centered studies that address one or more of the following Clinical Translational Research Award Focus Areas:
- Understanding and treating the features of TSC-Associated Neuropsychiatric Disorders (TAND) and reducing their impact, including pharmacological, behavioral, and surgical interventions
- Strategies for eradicating tumors associated with TSC and TSC-associated lymphangioleiomyomatosis (LAM), including gaining a deeper mechanistic understanding of TSC signaling pathways and tumor microenvironment
- Preventing epilepsy, improving treatment, and mitigating neurodevelopmental outcomes associated with TSC-related seizures
Independent investigators at or above the level of Assistant Professor (or equivalent) are eligible to be named as a PI on applications. An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by, or affiliated with, an eligible organization.
The anticipated direct costs budgeted for the entire period of performance for an FY22 TSCRP Clinical Translational Research Award will not exceed $1,000,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.